Baby Orajel Should Not Be Used in Infants Due to Risk of Life-Threatening Methemoglobinemia
Benzocaine-containing products like Baby Orajel pose a serious risk of methemoglobinemia in infants and young children and should be avoided entirely for teething pain. This is a potentially fatal condition where the blood cannot carry adequate oxygen to tissues.
Why Benzocaine is Dangerous in Infants
Infants are particularly vulnerable to methemoglobinemia from benzocaine exposure for several physiological reasons 1:
- Reduced enzyme activity: Infants have only 50-60% of adult levels of the enzyme (cytochrome b5 reductase) that protects against methemoglobin formation
- Fetal hemoglobin: Infants have higher levels of fetal hemoglobin (HbF), which oxidizes to methemoglobin more readily than adult hemoglobin
- Higher susceptibility: Even therapeutic application of benzocaine teething gels can cause severe toxicity
The 2016 Pediatrics guidelines explicitly warn that topical anesthetics like benzocaine carry risks of methemoglobinemia, local skin irritation, and toxicity, especially in preterm infants 2.
Documented Cases of Severe Harm
Multiple case reports demonstrate the serious nature of this risk:
- A 6-year-old developed a methemoglobin level of 69.9% (considered lethal) after using 7.5% benzocaine gel (Baby Orajel) for a toothache, presenting with cyanosis, vomiting, and lethargy 3
- A retrospective study found that among 99 pediatric benzocaine exposures, 5 patients had major clinical effects with methemoglobin levels ranging from 20.2-55%, requiring methylene blue treatment 4
- A 5-year-old developed severe methemoglobinemia from unattended self-use of benzocaine teething gel 5
Methemoglobin levels >70% are potentially lethal, and treatment is indicated at levels of 20% in symptomatic patients 1.
Lack of Efficacy
Beyond safety concerns, benzocaine shows no proven benefit for teething pain:
- A randomized controlled trial found that infants treated with topical benzocaine before lingual frenotomy actually cried longer (21.6 seconds) than controls (13.1 seconds) 6
- The study concluded that benzocaine use for analgesia in infants "should be discouraged" 6
Current Professional Stance
Despite FDA warnings issued in 2011 about avoiding benzocaine products for infant teething, a 2018 survey found that 63% of pharmacists would still inappropriately recommend benzocaine-containing products 7. This highlights a dangerous knowledge gap among healthcare providers.
What to Use Instead
The 2016 Pediatrics guidelines recommend nonpharmacologic strategies for teething pain 2:
- Facilitated tucking (holding the infant in a flexed position)
- Non-nutritive sucking (pacifiers)
- Breastfeeding or expressed human milk
- Oral sucrose solutions (0.1-1 mL of 24% sucrose, 2 minutes before discomfort)
These approaches have demonstrated effectiveness for mild to moderately painful procedures without the risk of methemoglobinemia.
Critical Pitfall to Avoid
The most dangerous pitfall is assuming that over-the-counter availability equals safety. Benzocaine concentrations in teething products range from 7.5-20%, and even the lower concentrations have caused severe methemoglobinemia requiring intensive care admission and methylene blue treatment 4, 3.
Parents and caregivers must be explicitly counseled to avoid all benzocaine-containing products for infant teething, regardless of their over-the-counter availability.